Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes

Bibliography

• HAFFNER SM, LEHTO S, RONNEMA T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl. Med. (1998) 339:229–234.
   PubMed Web of Science ®Google Scholar
• PANZRAM G: Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus: Diabetelegia (1987) 30:123–131.
   Google Scholar
• Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes UK Prospective Diabetes Study (UKPDS) Group (UKPDS 34). Lancet (1998) 352:854–865.
   PubMedGoogle Scholar
• •Improved cardiovascular outcomes with metformin in the UKPDS results support its use in all type 2 diabetic patients without contraindications to this agent
   Google Scholar
• Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UK Prospective Diabetes Study (UKPDS) Group (UKPDS 33). Lancet (1998) 352:837–853.
   Google Scholar
• •Intensive glycaemic control reduces the risk of microvascular complications in Type 2 diabetes.
   Google Scholar
• STRATTON IM, ADLER Al, NEIL HAW et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. (2000) 321:405–412.
   PubMed Web of Science ®Google Scholar
• •Epidemiological analysis of UKPDS results: the extent of protection from diabetic complications is proportional to the achieved reduction in AlC.
   Google Scholar
• The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2002 update. American Association of Clinical Endocrinologists. Endocrine Pract. (2002) 8\(Suppl. 1):40–82.
   Google Scholar
• Clinical Practice Recommendations. American Diabetes Association. Diabetes Care (1999) 22\(Suppl. 1):S1–5114.
   Google Scholar
• A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group. Diabet. Med. (1999) 16:716–730.
   PubMedGoogle Scholar
• PIMENTA W, KORYTKOWSKI M, MITRAKOU A et al.: Pancreatic 8-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA (1995) 273:1855–1861.
   Google Scholar
• DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care (1992) 15:318–368.
   PubMed Web of Science ®Google Scholar
• TURNER RC, CULL CA, FRIGHT F, HOLMAN RR: Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA (1999) 281:2005–2012.
   Google Scholar
• ••Diet-based therapy or oral antidiabetic monotherapy controls glycaemia for only a limited duration in most patients with Type 2 diabetes.
   Google Scholar
• DEFRONZO RA, GOODMAN AM: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N. Engl. Med. (1995) 333:541–549.
   PubMed Web of Science ®Google Scholar
• HAUPT E, KNICK B, KOSCHINSKY T, LIEBERMEISTER H, SCHNEIDER J, HIRSCHE H: Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab. (Paris) (1991) 27:224–231.
   Google Scholar
• HERMANN LS, SCHERSTEN B, MELANDER A: Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet. Med. (1994) 11:953–960.
   PubMed Web of Science ®Google Scholar
• MOSES R, CARTER J, SLOBODNIUK R et al.: Effect of repaglinide addition to metformin monotherapy on glycaemic control in patients with type 2 diabetes. Diabetes Care (1999) 22:119–124.
   PubMed Web of Science ®Google Scholar
• REASNER CA, GOKE B: Overcoming the barriers to effective glycaemic control for type 2 diabetes. Br. Diabetes Vase. Dis. (2002) 2:290–295.
   Google Scholar
• UKPDS: Correspondence. Lancet (1998) 352:1932–1934.
   Google Scholar
• FISMAN EZ, TENENBAUM A, BOYKO V et al.: Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.Clin. Cardiel (2001) 24:151–158.
   Google Scholar
• OLSSON J, LINDBERG G, GOTTSATER M et al: Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetelegia (2000) 43:558–560.
   PubMed Web of Science ®Google Scholar
• MORRISH NJ, STEVENS LK, HEAD J,FULLER JH, JARRETT RJ, KEEN H: A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk factors. Diabetologia (1990) 33:542–548.
   PubMed Web of Science ®Google Scholar
• SPIJKERMAN AM, DEKKER JM, NIJPELS G et al: Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur.j Clin. Invest. (2002) 32:924–930.
   PubMedGoogle Scholar
• JOHNSON JA, MAJUMDAR SR, SIMPSON SH, TOTH EL: Decreased mortality associated with the use of metformin compared with sulphonylurea monotherapy in type 2 diabetes. Diabetes Care (2002) 25:2244–2248.
   PubMed Web of Science ®Google Scholar
• •Further support for improved clinical outcomes in patients receiving metformin-based therapy.
   Google Scholar
• SCHEEN AJ, JAMINET C, LUYCKX AS, LEFEBVRE PJ: Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes. Int. [ Clin. Pharmacy]. Ther. Tarim] (1987) 25:70–76.
   Google Scholar
• DONAHUE SR, TURNER KC, PATEL S: Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance9 versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin. Pharmacokinet. (2002) 41:1301–1309.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of the enhanced pharmacokinetics and pharmacodynarnics of glyburide from the glyburide/metformin combination tablets described in this review, in comparison with glyburide and metformin co-administered.
   Google Scholar
• MARATHE PH, ARNOLD ME, MEEKER J, GREENE DS, BARBHAIYA RH: Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. Clin. Pharmacy]. (2000) 40:1494–1502.
   Google Scholar
• •Pharmacokinetics of glyburide/metformin combination tablets in volunteers.
   Google Scholar
• GARBER AJ, DAVIDSON J, MOORADIAN AD, PIPER BA: Effect of metformin/glyburide tablets on HbA I C in first-line treatment of type 2 diabetes. Diabetes Obes. Metab. (2002) 4:201–208.
   PubMed Web of Science ®Google Scholar
• ••A randomised, double-blind, placebo-controlled study in 806 diet-failed patients demonstrates superior efficacy of glyburide/metformin combination tablets in comparison with oral antidiabetic monotherapy.
   Google Scholar
• GARBER AJ, DONOVAN D, DANDONA P, BRUCE S, PARK J-S: Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J. Clin. Endocrine]. Metab. (2003) (In Press).
   Google Scholar
• MARRE M, HOWLETT H, LEHERT P, ALLAVOINE T: Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance9 in Type 2 diabetic patients inadequately controlled on metformin. Diabet. Med. (2002) 19:673–680.
   PubMed Web of Science ®Google Scholar
• ••A randomised, double-blind study in411 patients with hyperglycaemia despite previous metformin monotherapy, demonstrates superior efficacy of glyburide/metformin combination tablets in comparison with either agent given as monotherapy.
   Google Scholar
• BLONDE L, ROSENSTOCK R, MOORADIAN A, PIPER BA, HENRY D: Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulfonylurea therapy. Diabetes Obes. Metab. (2002) 4:368–375.
   PubMed Web of Science ®Google Scholar
• ••A randomised, double-blind study in639 patients with hyperglycaemia despite previous sulphonylurea monotherapy demonstrates superior efficacy of glyburide/metformin combination tablets in comparison with either agent given as monotherapy.
   Google Scholar
• GARBER A, MARRE M, BLONDE L, ALLAVOINE T, HOWLETT H, LEHERT P, CORNES M: Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance9 in type 2 diabetes. Diabetes Obes. Metab. (2003) 5:171–179.
   PubMed Web of Science ®Google Scholar
• GARBER AJ, BRUCE S, FIEDOREK FT: Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: An open-label extension study. Clin. flier: (2002) 24:1401–1413.
   Google Scholar
• ••Maintained efficacy following 1 year ofopen-label treatment with glyburide/metformin combination tablets in diet-failed patients.
   Google Scholar
• BLONDE L, ROSENSTOCKJ, PIPER BA, HENRY D: Durable antidiabetic effect of glyburide/metformin tablets as second-line therapy for type 2 diabetes. Diabetes (2001) 50 (supp1.2):A106 (abstract 423–P).
   Google Scholar
• ••Maintained efficacy following 1 year ofopen-label treatment with glyburide/metformin in patients uncontrolled by previous sulphonylurea monotherapy.
   Google Scholar
• GARBER A, SANKOH S, MOHIDEEN P, BRUCE S: Glyburide/metformin tablets versus metformin plus rosiglitazone in type 2 diabetes patients uncontrolled by metformin: attaining glycaemic goals. Diabetes (2003) 52\(Suppl. 1) :A119 (Abstract 513–P).
   Google Scholar
• ••A double-blind, randomised studysuggesting that an insulin secretagogue combined with an insulin sensitiser is more effective than a combination of two insulin sensitisers.
   Google Scholar
• WOFFORD M, SANKOH S, MOHIDEEN P, BRUCE S: Glyburide/metformin tablets versus pioglitazone as first-line treatment in type 2 diabetes: efficacy and safety. Diabetes (2003) 52\(Suppl. 1):A138 (Abstract 593–P).
   Google Scholar
• ••Superior efficacy of glyburide/metformincombination tablets versus piogjitazone monotherapy in Type 2 diabetic patients.
   Google Scholar
• DAILEY GE, BRUCE S, LEE HC: Rosiglitazone added to glyburide/metformin tablets as triple therapy in type 2 diabetes: distribution of HbAlc response. Endocrine Piaci (2002) 8(2):149 (Abstract 35).
   Google Scholar
• BLONDE L, WOGEN J, KREILICK C, SEYMOUR A: Glyburide/metformin tablets reduce AlC more than co-administered glyburide plus metformin in type 2 diabetic patients new to combination therapy. Diabetes (2003) 52\(Suppl. 1):A442 (Abstract 1917-PO).
   Google Scholar
• BOKHARI SU, GOPAL UM, DUCKWORTH WC: Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus. Am. J. Med. Sci. (2003) 325:66–69.
   PubMedGoogle Scholar
• DUCKWORTH W, MARCELLI M, PADDEN M et al.: Improvements in glycaemic control in type 2 diabetes patients switched from sulfonylurea co-administered with metformin to glyburide-metformin tablets. Managed Care Pharm. (2003) 9:256–262.
   PubMedGoogle Scholar
• ••Superior efficacy with glyburide/metformincombination tablets compared with a free combination of these agents.
   Google Scholar
• BLONDE L, WOGEN J, KREILICK C, SEYMOUR A: Switching to glyburide/metformin tablets from co-administration of glyburide plus metformin is associated with Al C reduction. Diabetes (2003) 52\(Suppl. 1):A442 (Abstract 1916-PO).
   Google Scholar
• AVIGNON A, RADAUCEANU A, MONNIER L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care (1997) 20: 1822-1826.
   Google Scholar
• HANEFELD M, KOEHLER C, SCHAPER F, FUCKER K, HENKEL E, TEMELKOVA-KURKTSCHIEV T: Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals Atherosclerosis (1999) 144:229–235.
   Google Scholar
• SAYDAH SH, MIRET M, SUNG J, VARAS C, GAUSE D, BRANCATI FL: Postchallenge hyperglycaemia and mortality in a national sample of U.S. adults. Diabetes Care (2001) 24:1397–1402.
   PubMed Web of Science ®Google Scholar
• •Utility of glyburide/metformin combination tablets in clinically important patient subgroups.
   Google Scholar
• DAILEY GE, MOHIDEEN P, FIEDOREK FT: Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycaemic control and dyslipidemia in an open-label extension study. Clin. Ther. (2002) 24:1426–1438.
   PubMedGoogle Scholar
• ••Improvements in lipid profiles during1 year of open-label treatment with glyburide/metformin combination tablets.
   Google Scholar
• WOLFE RR: Effects of insulin on muscle tissue. Curr: Opin. Clin. Nutr. Metab. Care (2000) 3:67–71.
   PubMedGoogle Scholar
• CHARPENTIER G, FLEURY F, KABIR M, VAUR L, HALIMIT S: Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet. Med. (2001) 16:828–834.
   Google Scholar
• EINHORN D, RENDELL M, ROSENZWEIG J, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Gin. Ther. (2000) 22:1395–1409.
   Google Scholar
• FONSECA V, ROSENSTOCK J, PAT WARDHAN R, SALZMAN A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA (2000) 283: 1695-1702.
   Google Scholar
• KIPNES MS, KROSNICK A, RENDELL MS, EGAN JVV, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycaemic control in patients with type 2 diabetes mellitus: a randomised placebo-controlled study. Ain. J. Med. (2001) 111:10–17.
   PubMed Web of Science ®Google Scholar
• WOLFFENBUTTEL BH, GOMIS R, SQUATRITO S, JONES NP, PAT WARDHAN RN: Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet. Med. (2000) 17:40–47.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, NADEAU D, BROWN A et al.: Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care (1998) 21:2050–2055.
   PubMed Web of Science ®Google Scholar
• KRENTZ AJ, FERNER RE, BAILEY CJ: Comparative tolerability profiles of oral antidiabetic agents. Drug Sal: (1994) 11:223–241.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ: Antidiabetic drugs. Br. J. Cardin]. (2000) 7:350–360.
   Google Scholar
• LALAU JD, RACE JM: Lactic acidosis in metformin therapy. Drugs (1999) 58\(Suppl. 1):55–60.
   Google Scholar
• LALAU JD, RACE JM: Lactic acidosis in metformin therapy: searching for a link with metformin in reports of `metformin-associated lactic acidosis'. Diabetes Obes. Metab. (2000) 2:1–7.
   PubMedGoogle Scholar
• SCARPELLO JHB: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br. J. Diabetes Vase. Dis. (2001):28–36.
   Google Scholar
• VEEHOF L, STEWART R, HAAIJER-RUSKAMP F, JONG BM: The development of polypharmacy. A longitudinal study. Fain. Piaci (2000) 17:261–267.
   Google Scholar
• PAES AHP, BAKKER A, SOE-AGNIE S-J:Impact of dosage frequency on patient compliance. Diabetes Care (1997) 20:1512–1517.
   PubMedGoogle Scholar
• BROWN JB, NICHOLS GA, GLAUBER HS, BAKST A: Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Ther. (1999) 21:1045–1057.
   PubMed Web of Science ®Google Scholar
• DONNAN PT, MACDONALD TM, MORRIS AD: Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet. Med. (2002) 19:279–284.
   PubMed Web of Science ®Google Scholar
• DAILEY G, KIM MS, LIAN JF: Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Gin. Tiler. (2001) 23:1311–1320.
   Google Scholar
• DAILEY G, KIM MS, LIAN JF: Patient compliance and persistence with anti-hyperglycaemic therapy: evaluation of a population of type 2 diabetic patients. J. hat. Med. Res. (2002) 30:71–79.
   Google Scholar
• ••Complex oral antidiabetic therapies hinderpatients' adherence to oral antidiabetic therapy.
   Google Scholar
• MORRIS AD, BRENNAN GM, MACDONALD TM, DONNAN PT: Population-based adherence to prescribed medication in Type 2 diabetes: a cause for concern. Diabetes (2000) 49\(Suppl. 1):A76.
   Google Scholar
• MELIKIAN C, WHITE TJ, VANDERPLAS A, DERJI CM, CHANGE: Adherence to oral antidiabetic therapy in a managed care organisation: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Gin. The]: (2002) 24:460–467.
   Google Scholar
• ••Superior adherence to therapy withglyburide/metformin combination tablets compared with the two agents co-administered, or after a switch from the free combination to combination tablets.
   Google Scholar
• CAMPBELL IW, HOWLETT HC: Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab. Rev (1995) 11\(Suppl. 1): S57–S62.
   Google Scholar
• JOINT NATIONAL COMMITTEE: Sixth national report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI). Arch. Intern. Med. (1997) 157:2413–2446.
   PubMed Web of Science ®Google Scholar
• GUIDELINES SUBCOMMITTEE: 1999 World Health Organisation - International Society of Hypertension. Guidelines for the management of hypertension. Hypertens. (1999) 17:151–183.
   Google Scholar